About GBT
GBT is a clinical-stage biopharmaceutical company determined to discover, develop and deliver innovative treatments that provide hope to underserved patient communities. GBT is developing its late-stage product candidate, voxelotor (previously called GBT440), for the treatment of sickle cell disease.
GBT Supports
Latest News
05-16-19 GBT Announces Upcoming Data Presentations at 24th European Hematology Association (EHA) Congress Supporting Voxelotor Sickle Cell Disease Program05-08-19 GBT Reports Recent Business Progress and First Quarter 2019 Financial Results05-06-19 GBT Announces New Employment Inducement Grants
more news »